In the setting of obesity, priming cancers with the PBP peptide to block prohibitin pathways is therefore expected to yield two benefits: (1) suppression of cancer metabolism and (2) conversion of a pro-tumor TME into a pro-immune microenvironment. The gene discussed is PHB1; the disease is neoplasm.